Introduction
Diabetes is one of the most common co-morbidities among patients with heart failure (HF).
1,2 Patients with both diabetes and HF, compared to those without diabetes, appear to have significantly different pathophysiologic pathways and a significantly increased risk of HF hospitalization and all-cause death. 3 -5 HF therapies such as angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists are as effective in patients with diabetes as in those without diabetes. 6 However, the presence of multiple co-morbidities may decrease the survival benefit of implantable cardioverter-defibrillators (ICDs). 7, 8 Furthermore, while diabetes has been demonstrated to be an independent risk predictor of arrhythmic death and sudden cardiac death (SCD), 9, 10 these patients also have an increased burden of non-arrhythmic death, 11 -13 which may not be reduced by ICDs. Despite being included in pivotal ICD trials, it is unclear if the presence of diabetes is associated with a reduction in the mortality benefit expected from primary prevention ICD implantation. In addition, diabetes is known to increase the risk of complications such as infections following surgery 14 ; however, limited data are available regarding the effect of diabetes on ICD-related complications and infections. 15 We conducted a patient-level combined analysis of four randomized controlled trials evaluating ICDs for primary prevention in order to assess: (i) outcomes associated with ICDs in addition to medical therapy vs. medical therapy alone among patients with diabetes; (ii) the burden of arrhythmic vs. non-arrhythmic death among patients with diabetes; and (iii) whether diabetes portends an increased risk of complications associated with ICD implantation.
Methods
Patient-level data from four major randomized controlled trials of ICDs were analysed: Multicenter Automatic Defibrillator Implantation Trial I (MADIT I), 16 MADIT II, 17 Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE), 18 and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 19 The amiodarone arm from the SCD-HeFT was excluded. These trials compared ICDs in addition to medical therapy (ICD group) vs. medical therapy alone (control group). Trial details and patient population characteristics have been described elsewhere. 7,16 -19 Inclusion criteria for this analysis were left ventricular ejection fraction ≤35%, time from myocardial infarction to randomization >40 days (where applicable), and availability of data on important covariates. Patients with New York Heart Association (NYHA) functional class IV HF (53 patients in the MADIT II trial) were also excluded. The presence of diabetes was based on the patient and site reported history of diabetes. There were no data available on type of diabetes, duration of diabetes, degree of control of diabetes, or type of antidiabetic treatment. Trial specific complications included hypotension, syncope, bradycardia or conduction defect, pulmonary embolism, atrial fibrillation, pneumothorax, bleeding, venous thrombosis, problems with a defibrillator lead, defibrillator generator malfunction, myocardial infarction, sustained ventricular tachycardia, ventricular fibrillation, shock (haemodynamic compromise), new or more advanced HF, postpericardiotomy syndrome, postoperative The primary endpoint of this analysis was all-cause death. The secondary endpoints were arrhythmic death, non-arrhythmic death, complications of ICD implantation, and appropriate/inappropriate ICD therapies. The definitions of arrhythmic deaths are based on each trial definition of adjudicated arrhythmic death (online supplementary Table  S1 ).
Statistical methods
Differences in baseline characteristics between patients with and without diabetes were described. Unadjusted all-cause mortality rates were described with Kaplan-Meier survival curves, and differences in survival between patients with ICDs and controls were assessed with log-rank tests for each group (patient with and without diabetes). We fitted Cox proportional hazards regression models for all-cause mortality combining data from each trial with a trial-specific random effect to account for the heterogeneity across trials. In our models, besides including treatment type (ICD vs. control) and diabetes status (and an interaction between these two), we included age, ejection fraction, sex, NYHA classification, race, QRS duration, presence of coronary artery disease, beta-blocker use, and ACEi use. Twenty-nine patients were removed due to missing variables. In sensitivity analyses, we also considered alternative model formulations where trial effects were accounted for with fixed effects model components, but the results were similar and thus were not included in the paper. Appropriate/inappropriate ICD therapies in patients with and without diabetes were compared using descriptive statistics. We conducted a sensitivity analysis for the outcome of all-cause mortality by including estimated glomerular filtration (eGFR) rate into the adjustment model; this sensitivity analysis did not include the DEFINITE trial as eGFR was not available. Similarly, we also fitted proportional sub-distribution hazard regression models to assess the competing risk of arrhythmic and non-arrhythmic deaths among patients with and without diabetes. 20 We stratified by the presence of ischaemia and evaluated the association of diabetes and all-cause mortality. Among patients with ICDs, we also assessed the risk of all-cause death and sudden death [using Cox proportional hazard models and sub-distribution hazard ratios (HR), respectively] among patients with diabetes vs. patients without diabetes adjusting for the same variables as described above.
Results

Patient demographics
The final cohort included 3359 patients (Figure 1 ). In total, there were 996 patients with diabetes of whom 512 were randomized to ICD with medical therapy and 484 to medical therapy alone. There were also 2363 patients without diabetes of whom 1266 were randomized to ICD with medical therapy and 1097 to medical therapy alone. Compared to those without diabetes (n = 2363), patients with diabetes (n = 996) were older, less often white, and had a greater burden of cardiovascular co-morbidities ( Table 1) . Patients with diabetes had higher use of diuretic therapy but equivalent use of ACEi and beta-blockers. Demographics by randomized treatment arm demonstrates similar characteristics (online supplementary Table S2 ). 
Implantable cardioverter-defibrillators among patients with diabetes
At 5 years, relative to the number of patients initially enrolled in the study, a greater proportion of patients with diabetes died (46%) compared with those without diabetes (30%). Overall, ICDs were associated with a reduced risk of all-cause death [unadjusted HR 0.70, 95% confidence interval (CI) 0.60-0.81; adjusted HR (aHR) 0.68, 95% CI 0.57-0.78]. Among patients with diabetes, the ICD was not significantly associated with a reduced risk of all-cause mortality at 5 years (per 100 patient-years; 10.49 with ICD vs. 12.06 without ICD; unadjusted HR 0.87, 95% CI 0.65-1.18; aHR 0.88, 95% CI 0.7-1.12; Figure 2A ). In comparison, in patients without diabetes, the ICD significantly reduced the risk of all-cause death (per 100 patient-years; 5.34 with ICD vs. 8.78 without ICD; unadjusted HR 0.61, 95% CI 0.50-0.73; aHR 0.56, 95% CI 0.46-0.67; Figure 2B ). The presence of diabetes was associated with reduced survival benefit from ICDs (adjusted P-value for interaction between ICD treatment and diabetes in relation to all-cause death: P = 0.015). The sensitivity analysis, which also adjusted for eGFR, did not change these findings (adjusted P-value for interaction between ICD treatment and diabetes in relation to all-cause death: P = 0.015).
In the analysis of competing risks of arrhythmic and non-arrhythmic deaths, ICDs were associated with a reduced risk of arrhythmic death among patients with diabetes [per 100 patient-years; 2.34 with ICD vs. term remained significant (P-value for interaction between ICD treatment and diabetes in relation to arrhythmic death: P = 0.036).
These results indicate a reduced ICD benefit for arrhythmic death among those with diabetes. The ICD was not associated with a reduced risk of non-arrhythmic death in patients with diabetes (adjusted sHR 1.16, 95% CI 0.87-1.53) or without diabetes (adjusted sHR 0.81, 95% CI 0.65-1.02). Among patients with ischaemic cardiomyopathy, the presence of an ICD was associated with a reduced risk of all-cause mortality in patients without diabetes (aHR 0.59, 95% CI 0.47-0.74) but not among patients with diabetes (aHR 0.76, 95% CI 0.58-1). However, we could not rule out no interaction (P = 0.17).
A coefficient plot of the variables used in the multivariable analysis is presented as Figure 3 .
Distribution of arrhythmic and non-arrhythmic death
The rates of deaths from arrhythmic and non-arrhythmic causes were greater in patients with diabetes (online supplementary Figure  S1A ) compared with those without diabetes (online supplementary Figure S1B ), across all time points and regardless of the study arm. Overall, among patients with diabetes, 280 patients died [128 (46%) with ICD vs. 152 (54%) with medical therapy alone]. Among those without diabetes, 437 died [178 (41%) with ICD vs. 259 (59%) with medical therapy alone]. In comparison to patients without diabetes, non-arrhythmic deaths formed a greater proportion of overall death (online supplementary Figure S1 ). Among patients randomized to receive an ICD, the risk of all-cause death was higher in patients with diabetes compared to patients without 
Appropriate and inappropriate implantable cardioverter-defibrillator therapies
Data for appropriate and inappropriate shocks were available from MADIT II and SCD-HeFT. Among patients with diabetes, there were 454 patients with at least one shock: of these, 81 (18%) patients had at least one appropriate shock and 373 (82%) patients had at least one inappropriate shock. In patients without diabetes, 1009 patients had at least one shock: of these, 204 (20%) patients had at least one appropriate shock and 805 (80%) patients had at least one inappropriate shock. There was no significant difference in the proportion of appropriate and inappropriate shocks between patients with and those without diabetes (P = 0.32). In the MADIT II and SCD-HeFT trials, for patients without diabetes, the average number of appropriate shocks was 1.08 [standard deviation (SD) 2.75; range 0-33], while for patients with diabetes, the average was 
Discussion
We conducted a patient-level combined analysis of four primary prevention ICD trials including 3359 patients to evaluate the comparative effectiveness of ICDs and medical therapy vs. medical therapy alone in patients with and without diabetes. Our results have the following major findings: (i) ICD with medical therapy vs. medical therapy alone was significantly associated with a reduced risk of all-cause death in patients without diabetes but not in patients with diabetes; (ii) ICDs are associated with a reduced risk of arrhythmic death in all patients, yet the magnitude of benefit in patients with diabetes is significantly reduced; (iii) non-arrhythmic death accounts for the majority of all-cause death among patients with diabetes; and (iv) patients with diabetes, compared with those without diabetes, did not experience more complications including infection associated with ICD implantations.
Reduced benefit of implantable cardioverter-defibrillators in patients with diabetes
A diabetes, the arrhythmic and non-arrhythmic death rates in patients randomized to medical therapy are similar up to 2 years; this finding suggests a large burden of arrhythmic death relative to the overall death. Among patients with diabetes randomized to medical therapy, the rate of non-arrhythmic death exceeds arrhythmic death earlier suggesting that non-arrhythmic death forms a larger burden of all-cause death. The large competing risk of non-arrhythmic death in patients with diabetes may be related to the greater burden of associated co-morbidities; prior studies have demonstrated that a greater burden of co-morbidities increases risk for non-arrhythmic death and decreases the benefit of ICDs. 7, 8, 23 Our results have significant implications as there is an ongoing study (MADIT S-ICD, ClinicalTrials.gov ID: NCT02787785) evaluating the benefit of ICDs in patients with diabetes and mildly reduced ejection fraction. In addition to competing risk, it is unclear whether the presence of diabetes inherently decreases responsiveness to ICD therapies. Potential additional explanation for the reduced benefit of ICDs in patients with diabetes may relate to hypoglycaemia, which may arise from antidiabetic treatments. Hypoglycaemia has been associated with increased risk of arrhythmic death 24 and it is unclear if ICD therapies are effective in reducing arrhythmic death in this setting.
In our study, the use of HF medical therapies was lower than that seen in more contemporary HF trials. Among patients with HF, mineralocorticoid receptor antagonists 25, 26 and sacubitril/valsartan have demonstrated a significant reduction in cardiovascular mortality and possibly sudden death. 27 A recent analysis has suggested that the risk of sudden death among patients enrolled in HF trials has declined over time. 28 These results emphasize the beneficial impact of evidence-based therapies on the risk of sudden death. Overall, our analysis demonstrates that patients with diabetes have a higher risk of sudden death compared to those without diabetes, emphasizing the critical need for appropriate evidence-based therapies.
Similarly, empagliflozin, a sodium-glucose co-transporter 2 inhibitor, has demonstrated a significant reduction in cardiovascular mortality among patients with type 2 diabetes mellitus and cardiovascular risk factors. 29, 30 The Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial failed to demonstrate an improvement in the primary outcome of all-cause mortality with ICDs with medical therapy vs. medical therapy alone among patients with non-ischaemic cardiomyopathy. 31 One speculated reason was the high prevalence of more contemporary HF medical and device therapies. contemporary HF and anti-hyperglycaemic drugs among patients with diabetes would further alter the magnitude of ICD benefit are warranted. In our study, a significant benefit in mortality associated with ICD use was seen among patients with ischaemic cardiomyopathy. These results support professional guidelines which recommend that appropriate patients with ischaemic cardiomyopathy should be considered for ICD placement. Whether patients with diabetes and non-ischaemic cardiomyopathy have mortality benefit associated with ICD needs further evaluation.
to identify those who have the highest risk of sudden death over other causes of death may identify those who will preferentially benefit from ICD therapies. Despite the increased risk of sudden death among patients with diabetes, the decreased magnitude of benefit of ICD in patients with diabetes compared to patients without diabetes further highlights the importance of competing risk in this population.
Risk of implantable cardioverter-defibrillator insertion complications in patients with diabetes
Across a spectrum of surgical procedures, diabetes has been associated with a significantly increased risk of postoperative complications including wound/incision infections. 14 While the reasons are unclear, multiple mechanisms may be implicated such as vascular changes, impaired wound healing, white blood cell dysfunction, immune suppression, and exogenous intravenous glucose utilization. Our results suggest that there is no increase in postoperative complications including infections among patients with diabetes, but it is important to note the relatively small number of events available for this analysis.
Inappropriate implantable cardioverter-defibrillator shocks in patients with diabetes
Our analysis identified no significant differences in the number of patients who have appropriate or inappropriate shocks among those with and without diabetes. Patients with diabetes may be relatively less mobile, and thereby decreasing the risk of exercise-induced tachycardia and inappropriate shocks. Furthermore, patients with diabetes are more likely to be on a statin, which has shown to decrease the incidence of atrial fibrillation and potentially inappropriate shocks.
Strengths and limitations
This analysis was performed on a combined population from several randomized controlled trials which were heterogeneous in their populations. This analysis is subject to the limitations of a post-hoc analysis including being underpowered to detect a difference in all-cause mortality between treatment arms among patients with diabetes; however, the significant interaction term between patients with and without diabetes for all-cause mortality indicates a reduction in the magnitude of ICD benefit among patients with diabetes. Similarly, the reduction in the magnitude of effect of ICD was seen for the outcome of arrhythmic death.
The baseline characteristics between the randomized arms were not balanced in the subgroup of patients with and without diabetes. We evaluated patients with diabetes compared to those without diabetes and adjusted for baseline characteristics and our results remained consistent after multivariable adjustments. The analysis of inappropriate shocks would need further validation in a contemporary cohort given that ICD programming is likely different from the time in which these trials were conducted. These data are derived from randomized trials focused on primary prevention and so the findings should not be generalized to patients eligible for secondary prevention ICD; however, this remains one of the largest cohorts of ICD eligible patients with diabetes and HF for whom adjudicated causes of death are available.
Conclusion
Among patients with HF and diabetes, a pooled analysis of the major ICD trials failed to demonstrate a reduced risk of all-cause mortality associated with ICDs. While ICDs were associated with a reduced risk of arrhythmic death in all patients, the magnitude of benefit was significantly reduced in patients with diabetes. Our findings may be due to the increased burden of competing non-arrhythmic death among patients with diabetes. Additional studies are needed to further evaluate the effectiveness of ICDs in patients with diabetes.
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